Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I safety and immunogenicity study of aAVC-CoV-2 in adults with antibody-producing failure
jRCT2063240097Phase 1Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Dec 2024
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of aAVC-CoV-2 in coronavirus disease 2019 (COVID-19) (2 cohorts), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Safety. Started Dec 2024; status: active, not recruiting.
02
Drugs
aAVC-CoV-2
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2063240097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2063240097.